LXEO: JP Morgan Lowers Target
JP Morgan maintains Overweight on Lexeo Therapeutics, lowers price target to $9
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ: LXEO ) with a Overweight and lowers the price target from $12 to $9.
JP Morgan maintains Overweight on Lexeo Therapeutics, lowers price target to $9
JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ: LXEO ) with a Overweight and lowers the price target from $12 to $9.